# Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

> **NCT01025843** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** MK-5478
- **DRUG:** Comparator: Candesartan cilexetil
- **DRUG:** Comparator: Pbo

## Key facts

- **NCT ID:** NCT01025843
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-01
- **Primary completion:** 2010-05-01
- **Final completion:** 2010-05-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025843, "Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01025843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*